Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Condensed Consolidated Statements of Operations
Net Revenues	$ 64,477	$ 54,521
Operating Expenses
Cost of sales (excluding depreciation and amortization)	34,271	19,985
Research and development	5,274	2,968
Selling, general, and administrative	28,817	17,587
Depreciation and amortization	14,557	10,898
Contingent consideration fair value adjustment	753	0
Purified Cortrophin Gel pre-launch charges	0	38
Total Operating Expenses	83,672	51,476
Operating (Loss)/Income	(19,195)	3,045
Other Expense, net
Interest expense, net	(6,613)	(2,454)
Other expense, net	(89)	(515)
(Loss)/Income Before Benefit for Income Taxes	(25,897)	76
Benefit for income taxes	5,767	10
Net (Loss)/Income	(20,130)	86
Dividends on Series A convertible preferred stock	(405)	0
Net (Loss)/Income Available to Common Shareholders	$ (20,535)	$ 81
Basic and Diluted (Loss)/Earnings Per Share:
Basic (Loss)/Earnings Per Share	$ (1.27)	$ 0.01
Diluted (Loss)/Earnings Per Share	$ (1.27)	$ 0.01
Basic Weighted-Average Shares Outstanding	16,137	12,004
Diluted Weighted-Average Shares Outstanding	16,137	12,017